vs
AMC Networks Inc.（AMCX）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
AMC Networks Inc.的季度营收约是ICU MEDICAL INC的1.1倍（$594.8M vs $540.7M），ICU MEDICAL INC净利率更高（-2.9% vs -9.3%，领先6.4%），AMC Networks Inc.同比增速更快（-0.8% vs -14.1%），AMC Networks Inc.自由现金流更多（$40.4M vs $36.0M），过去两年AMC Networks Inc.的营收复合增速更高（-0.1% vs -2.3%）
AMC网络公司是总部位于纽约市的美国独立大众传媒娱乐集团，旗下拥有AMC、BBC美国台、IFC、圣丹斯电视、We TV等多个有线频道，还经营纽约IFC中心艺术影院、独立电影公司、动漫版权发行商，以及AMC+、Acorn TV等多个付费订阅流媒体服务。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
AMCX vs ICUI — 直观对比
营收规模更大
AMCX
是对方的1.1倍
$540.7M
营收增速更快
AMCX
高出13.4%
-14.1%
净利率更高
ICUI
高出6.4%
-9.3%
自由现金流更多
AMCX
多$4.5M
$36.0M
两年增速更快
AMCX
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $594.8M | $540.7M |
| 净利润 | $-55.5M | $-15.7M |
| 毛利率 | 49.7% | 37.5% |
| 营业利润率 | -8.6% | 1.0% |
| 净利率 | -9.3% | -2.9% |
| 营收同比 | -0.8% | -14.1% |
| 净利润同比 | 80.5% | 34.0% |
| 每股收益（稀释后） | $-0.97 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMCXICUI
| Q4 25 | $594.8M | $540.7M | ||
| Q3 25 | $561.7M | $537.0M | ||
| Q2 25 | $600.0M | $548.9M | ||
| Q1 25 | $555.2M | $604.7M | ||
| Q4 24 | $599.3M | $629.8M | ||
| Q3 24 | $599.6M | $589.1M | ||
| Q2 24 | $625.9M | $596.5M | ||
| Q1 24 | $596.5M | $566.7M |
净利润AMCXICUI
| Q4 25 | $-55.5M | $-15.7M | ||
| Q3 25 | $76.5M | $-3.4M | ||
| Q2 25 | $50.3M | $35.3M | ||
| Q1 25 | $18.0M | $-15.5M | ||
| Q4 24 | $-284.5M | $-23.8M | ||
| Q3 24 | $41.4M | $-33.0M | ||
| Q2 24 | $-29.2M | $-21.4M | ||
| Q1 24 | $45.8M | $-39.5M |
毛利率AMCXICUI
| Q4 25 | 49.7% | 37.5% | ||
| Q3 25 | 48.2% | 37.4% | ||
| Q2 25 | 52.7% | 37.9% | ||
| Q1 25 | 51.8% | 34.7% | ||
| Q4 24 | 51.2% | 36.1% | ||
| Q3 24 | 52.0% | 34.8% | ||
| Q2 24 | 55.2% | 34.8% | ||
| Q1 24 | 54.5% | 32.7% |
营业利润率AMCXICUI
| Q4 25 | -8.6% | 1.0% | ||
| Q3 25 | 9.9% | 2.6% | ||
| Q2 25 | 10.7% | 1.9% | ||
| Q1 25 | 11.6% | 2.1% | ||
| Q4 24 | -42.4% | 6.0% | ||
| Q3 24 | 15.6% | 1.4% | ||
| Q2 24 | 1.7% | 1.3% | ||
| Q1 24 | 18.5% | -1.9% |
净利率AMCXICUI
| Q4 25 | -9.3% | -2.9% | ||
| Q3 25 | 13.6% | -0.6% | ||
| Q2 25 | 8.4% | 6.4% | ||
| Q1 25 | 3.3% | -2.6% | ||
| Q4 24 | -47.5% | -3.8% | ||
| Q3 24 | 6.9% | -5.6% | ||
| Q2 24 | -4.7% | -3.6% | ||
| Q1 24 | 7.7% | -7.0% |
每股收益（稀释后）AMCXICUI
| Q4 25 | $-0.97 | $-0.63 | ||
| Q3 25 | $1.38 | $-0.14 | ||
| Q2 25 | $0.91 | $1.43 | ||
| Q1 25 | $0.34 | $-0.63 | ||
| Q4 24 | $-6.23 | $-0.97 | ||
| Q3 24 | $0.76 | $-1.35 | ||
| Q2 24 | $-0.66 | $-0.88 | ||
| Q1 24 | $1.03 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $502.4M | — |
| 总债务越低越好 | $1.8B | — |
| 股东权益账面价值 | $981.9M | $2.1B |
| 总资产 | $3.9B | $4.1B |
| 负债/权益比越低杠杆越低 | 1.78× | — |
8季度趋势，按日历期对齐
现金及短期投资AMCXICUI
| Q4 25 | $502.4M | — | ||
| Q3 25 | $716.8M | — | ||
| Q2 25 | $866.4M | — | ||
| Q1 25 | $870.2M | — | ||
| Q4 24 | $784.6M | $308.6M | ||
| Q3 24 | $816.4M | $312.5M | ||
| Q2 24 | $802.6M | $302.6M | ||
| Q1 24 | $690.5M | $251.4M |
总债务AMCXICUI
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.3B | — |
股东权益AMCXICUI
| Q4 25 | $981.9M | $2.1B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $971.7M | $2.1B | ||
| Q1 25 | $888.8M | $2.0B | ||
| Q4 24 | $855.6M | $2.0B | ||
| Q3 24 | $1.1B | $2.0B | ||
| Q2 24 | $1.1B | $2.0B | ||
| Q1 24 | $1.1B | $2.1B |
总资产AMCXICUI
| Q4 25 | $3.9B | $4.1B | ||
| Q3 25 | $4.2B | $4.1B | ||
| Q2 25 | $4.4B | $4.1B | ||
| Q1 25 | $4.3B | $4.2B | ||
| Q4 24 | $4.4B | $4.2B | ||
| Q3 24 | $4.8B | $4.3B | ||
| Q2 24 | $4.9B | $4.3B | ||
| Q1 24 | $4.9B | $4.3B |
负债/权益比AMCXICUI
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.82× | — | ||
| Q2 25 | 2.27× | — | ||
| Q1 25 | 2.62× | — | ||
| Q4 24 | 2.73× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 2.26× | — | ||
| Q1 24 | 2.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.2M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $40.4M | $36.0M |
| 自由现金流率自由现金流/营收 | 6.8% | 6.6% |
| 资本支出强度资本支出/营收 | 1.5% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $272.4M | $91.8M |
8季度趋势，按日历期对齐
经营现金流AMCXICUI
| Q4 25 | $49.2M | $60.6M | ||
| Q3 25 | $44.8M | $56.7M | ||
| Q2 25 | $102.8M | $11.2M | ||
| Q1 25 | $108.8M | $51.3M | ||
| Q4 24 | $58.1M | $40.2M | ||
| Q3 24 | $62.2M | $36.1M | ||
| Q2 24 | $104.4M | $82.0M | ||
| Q1 24 | $150.9M | $45.8M |
自由现金流AMCXICUI
| Q4 25 | $40.4M | $36.0M | ||
| Q3 25 | $42.0M | $27.6M | ||
| Q2 25 | $95.7M | $-8.5M | ||
| Q1 25 | $94.2M | $36.7M | ||
| Q4 24 | $37.6M | $16.1M | ||
| Q3 24 | $53.9M | $16.2M | ||
| Q2 24 | $95.2M | $62.5M | ||
| Q1 24 | $144.1M | $29.9M |
自由现金流率AMCXICUI
| Q4 25 | 6.8% | 6.6% | ||
| Q3 25 | 7.5% | 5.1% | ||
| Q2 25 | 16.0% | -1.5% | ||
| Q1 25 | 17.0% | 6.1% | ||
| Q4 24 | 6.3% | 2.6% | ||
| Q3 24 | 9.0% | 2.7% | ||
| Q2 24 | 15.2% | 10.5% | ||
| Q1 24 | 24.2% | 5.3% |
资本支出强度AMCXICUI
| Q4 25 | 1.5% | 4.6% | ||
| Q3 25 | 0.5% | 5.4% | ||
| Q2 25 | 1.2% | 3.6% | ||
| Q1 25 | 2.6% | 2.4% | ||
| Q4 24 | 3.4% | 3.8% | ||
| Q3 24 | 1.4% | 3.4% | ||
| Q2 24 | 1.5% | 3.3% | ||
| Q1 24 | 1.1% | 2.8% |
现金转化率AMCXICUI
| Q4 25 | — | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 2.04× | 0.32× | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMCX
| Subscription And Circulation | $314.8M | 53% |
| Advertising | $124.9M | 21% |
| Other | $79.1M | 13% |
| License | $74.8M | 13% |
| Related Party | $1.2M | 0% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
